Associate Scientist​/Scientist , LNP Formulations

Associate Scientist/Scientist I, LNP Formulations

Cambridge, MA

Mirai Bio is a privately-held, Flagship-founded biotechnology company that is delivering genetic medicines from promise to performance. Mirai was built to solve one of the field's central challenges: achieving precise, scalable delivery of diverse nucleic acid payloads to specific cells and tissues, particularly beyond the liver. By combining a large and growing proprietary in vivo biodistribution dataset, machine learning-guided lipid nanoparticle optimization, modular targeted particle design, and integrated translation and manufacturing capabilities, Mirai helps partners accelerate development, reduce technical risk, and pursue high-value programs making delivery a strategic advantage.

We are seeking collaborative, relentless problem solvers that share our passion for defining the future of genetic medicines together.

Mirai Bio is seeking a scientist to advance our lipid nanoparticle (LNP) delivery platform for nucleic acid therapeutics. Mirai Bio is seeking a highly talented and motivated individual to develop and optimize lipid nanoparticle (LNP) formulations. The successful candidate will contribute to both platform innovation and preclinical pipeline programs, working at the interface of formulation science, Chemistry, analytical characterization, and process development.

• Design, formulate, and characterize lipid nanoparticle (LNP) systems for nucleic acid delivery across early research and preclinical development stages
• Develop and optimize formulation processes, including microfluidic mixing and scale-up approaches (e.g., TFF, ultrafiltration)
• Screen and evaluate novel ionizable lipids and LNP compositions; analyze structure–function relationships to improve delivery performance
• Troubleshoot formulation and process challenges to enhance robustness, reproducibility, and scalability
• Generate high-quality, reproducible data and maintain thorough documentation in electronic lab notebooks
• Prepare LNP formulations to support internal research and partner programs
• Collaborate cross-functionally with analytical, translational, and Tech development teams to advance platform goals
• Present data and insights clearly to internal teams and contribute to scientific discussions and decision-making

• Ph.D. and 0-1 years or 4+ years (M.Sc.) or 6+ years (B.Sc.) of relevant industry experience in LNP formulation optimizations and drug delivery with strong background in nucleic acid therapeutics and education in life sciences or engineering (Pharmaceutical Sciences, Biomedical Engineering, Biochemistry, etc)
• Level (Associate Scientist or Scientist I) will be determined based on experience, technical expertise, and demonstrated impact.
• Hands-on experience in nanoparticle or LNP formulation and characterization
• Strong understanding of drug delivery systems, particularly for nucleic acid therapeutics
• Experience with nanoparticle characterization techniques (e.g., DLS, zeta potential, fluorescence-based assays such as Ribogreen, chromatography)
• Demonstrated ability to design, execute, and troubleshoot experiments independently
• Strong data analysis, documentation, and communication skills

• Familiarity with formulation process technologies (e.g., microfluidic mixers, pumping systems, TFF)
• Experience with high-throughput formulation screening approaches
• Knowledge of lipid chemistry, ionizable lipid design, or bioconjugation techniques
• Experience supporting in vivo studies or translating formulations from research to preclinical scale

• Scientific rigor and attention to data quality and reproducibility
• Curiosity and a problem-solving mindset
• Ability to work both independently and collaboratively in a fast-paced environment
• Clear and concise communication across disciplines
• Ownership and accountability in driving projects forward

Cambridge, MA

Flagship Pioneering invents and builds platform companies, each with the potential for multiple products that transform human health, sustainability and beyond. Since its launch in…